PCI BIOTECH HOLDING ASA: årsregnskap 2022 vs 2021
Shrank 24% on revenue, weaker earnings, cash halved-plus
approved 2023-05-25; registry 2023-06-14; journal 2023 446194
Summary
What changed
Comparing Årsregnskap 2022 with 2021 for PCI BIOTECH HOLDING ASA. Revenue 6.27m NOK → 4.75m NOK (-24.3%). Net result -154.91m NOK → -467.24m NOK. Equity 544.57m NOK → 76.03m NOK.
On the constructive side: owners injected capital. Pressures included: revenue fell; operating result weakened; net result weakened.
Also worth watching: sharp cash drawdown; book investments changed. All figures are taken from the published annual accounts for PCI BIOTECH HOLDING ASA.
At a glance
Scorecard
What improved
-
↑
Owners injected capital
Paid-in equity rose 504.8k NOK → 111.98m NOK (+111.47m NOK). Reported fact
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 6.27m NOK to 4.75m NOK (-24.3% YoY). Calculated
-
↓
Operating result weakened
Operating result -4.97m NOK → -5.22m NOK (op. margin -79.2% → -109.9%). Calculated
-
↓
Net result weakened
Net result -154.91m NOK → -467.24m NOK (net margin -2469.6% → -9836.7%). Calculated
-
↓
Equity eroded
Book equity 544.57m NOK → 76.03m NOK (equity ratio 99.8% → 98.5%). Calculated
-
↓
Cash fell
Bank deposits 26.48m NOK → 628.0k NOK (-97.6% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (26.48m NOK → 628.0k NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Book investments changed
Investment / intangible book value 504.19m NOK → 69.16m NOK. Reported fact